BMS-813160 Uses, Dosage, Side Effects and more
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
Trade Name | BMS-813160 |
Generic | BMS-813160 |
Type | |
Formula | C25H40N8O2 |
Weight | Average: 484.649 Monoisotopic: 484.32742256 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |